Doug Ingram, Sarepta CEO
January 11, 2022 07:26 AM EST
R&D
Cell/Gene Tx

Sarep­ta's sec­ond shot at show­ing its Duchenne gene ther­a­py de­liv­ers pos­i­tive da­ta but un­der­whelms — shares tum­ble

Amber Tong

When Sarep­ta re­vealed last Jan­u­ary that its gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy had failed the key func­tion­al end­point in Part 1 of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times